Amondys 45 (casimersen) for a UAE family: what the pathway looks like in 2026

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

A UAE family of a son with Duchenne muscular dystrophy walks into this decision with more than a treatment question. There is a clinical question, a genetic question, a regulatory question, a financial one, and a family one, and they all need answers in roughly the same week. This page is meant to be the first honest read you get on Amondys 45 in the UAE, from the team that would coordinate it for your son if you decided to go forward. We assume your paediatric neurologist has either raised it with you or you have raised it with them.

We will be specific about the genetic-testing gate that decides whether Amondys 45 is even relevant for your son, what the rest of the workup decides, how the UAE named-patient pathway works, what it costs in AED and US dollars per year for a lifelong weekly infusion, where the infusion can be given in the UAE, and what life looks like once weekly therapy is in place.

The genetic gate: this drug is for a specific subset of DMD families

Amondys 45 is an exon-skipping therapy. It works by forcing the cell's splicing machinery to skip exon 45 during dystrophin mRNA processing, restoring the reading frame across the patient's deletion and producing an internally truncated but partially functional dystrophin protein. This mechanism only helps families whose son's DMD mutation is amenable to exon 45 skipping. Approximately 8 percent of DMD patients fall into this group. Most do not. That is the first conversation, and it has to happen before anything else.

If your son has already had whole-gene sequencing or MLPA done, your paediatric neurologist will read out the deletion or duplication boundary and tell you immediately whether exon 45 skipping is the right mechanism. If your son has not been tested, this is the first appointment. KFSHRC's molecular genetics service in Riyadh, Tawam Hospital genetics in Al Ain, the SKMC paediatric neurology service in Abu Dhabi, and American Hospital Dubai's genetics referral pathway can all run or refer for the test. Results typically return in 4 to 8 weeks for whole-gene sequencing; MLPA is faster but covers only common deletion-duplication patterns.

If exon 45 skipping is not the right mechanism for your son, this page is the wrong page. We will be direct about what the right page is. Exondys 51 (eteplirsen) is for exon 51 skipping. Vyondys 53 (golodirsen) and Viltepso (viltolarsen) are for exon 53 skipping. Elevidys is a one-time gene-therapy option for ambulatory boys aged 4 and older, independent of which exon is the boundary. Reach out and we will talk through your son's specific picture. We coordinate cases for any of these drugs, not just Amondys 45.

What Amondys 45 actually is, in plain terms

Amondys 45 is a weekly intravenous infusion. The active ingredient is casimersen, a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide. PMO is a synthetic chemistry, not derived from human or animal sources. The molecule binds to a specific stretch of the pre-mRNA of the DMD gene and tells the splicing machinery to leave exon 45 out of the final mRNA. With exon 45 removed, the reading frame across the deletion is restored, and the muscle cell can produce a shortened but partially functional dystrophin protein. The level of dystrophin produced is modest in measured biopsy data; what the clinical data describe is a slowing of functional decline against the natural history of DMD, not restoration of normal function.

What Amondys 45 is not is a cure. The benefit is real but partial, and it requires continuous weekly dosing because the molecule's effect is at the splicing stage and the molecule clears the body between doses. There is no taper, no stop point, no "course completed." The weekly schedule is lifelong.

The pivotal ESSENCE trial documented a statistically significant increase in dystrophin protein expression by western blot. Long-term functional follow-up against natural-history cohorts is the basis for the FDA accelerated approval granted in February 2021. Your neurologist will walk you through the most recent data published, including the 6-minute walk test, North Star Ambulatory Assessment, and forced vital capacity trajectories in the ESSENCE long-term follow-up cohort.

We will also be honest that the European Medicines Agency reviewed Amondys 45 in 2024 and issued a negative CHMP opinion. The EMA concluded that the available evidence was not sufficient to support marketing authorisation in the European Union as of that date. We mention this because UAE families occasionally consult European clinicians and the divergence between the FDA and EMA decisions deserves a straight answer. Your neurologist can put the FDA-EMA divergence in clinical context against your son's specific situation.

The rest of the workup

Beyond the genetic confirmation that exon 45 skipping is the right mechanism, three more results need to land before the pathway opens.

First, baseline renal function. Casimersen has a post-marketing warning for renal toxicity. Serum creatinine, urinalysis, and where available cystatin C are the baseline labs. Active renal impairment requires clinical workup before infusion can be scheduled, and quarterly renal monitoring continues for the life of therapy.

Second, baseline cardiac function. DMD cardiomyopathy presents later in the disease course; echocardiography is the standard baseline, with intervals set per centre protocol. Amondys 45 itself is not cardiotoxic in current data, but cardiac surveillance is part of standard DMD management and continues regardless.

Third, baseline functional assessments and vascular access planning. The 6-minute walk test (for ambulatory patients), the North Star Ambulatory Assessment, and forced vital capacity provide the functional baseline against which response is tracked. Because the infusion is weekly and lifelong, vascular access is a real consideration. Many paediatric patients on Amondys 45 have a port placed once the decision is committed; weekly peripheral IV access is operationally hard over years.

A clinical rationale letter from your paediatric neurologist will document the genetic confirmation, the renal and cardiac baselines, the functional baselines, the rehabilitation plan, the steroid regimen (deflazacort or prednisone, which continues alongside Amondys 45), and the requested treatment.

The UAE regulatory pathway: how it actually works in 2026

The Emirates Drug Establishment, which absorbed 44 of the Ministry of Health and Prevention's regulatory functions by early 2026, is now the federal authority you and your treating hospital file through. ``. In the absence of EDE registration on the standard list, the named-patient mechanism is the route. It is filed via ede.gov.ae by the hospital's import pharmacy on the treating neurologist's behalf. The Department of Health Abu Dhabi or Dubai Health Authority adds the emirate-level layer depending on where the infusion is given.

In our experience coordinating named-patient gene-therapy and exon-skipping cases in the UAE, EDE approval on a complete, well-documented file takes three to six weeks from filing. Renewal cycles thereafter (because Amondys 45 supply is continuous and weekly) are typically simpler than the initial approval but require advance planning so that supply continuity is never at risk. Reserve Meds maintains the renewal calendar as part of case management.

In the UAE, the paediatric neurology hubs that can administer Amondys 45 include Tawam Hospital paediatric neurology in Al Ain, Sheikh Khalifa Medical City paediatric neurology in Abu Dhabi, Sheikh Shakhbout Medical City, American Hospital Dubai paediatric neurology, and Mediclinic City Hospital paediatric neurology. For families outside Abu Dhabi or Dubai, our coordination routes the weekly infusion to a centre that fits the family's home base, with home infusion programmes evaluated as an option once the first several infusions are completed safely at the qualified centre.

The cost conversation, in the form a UAE family needs

This is the conversation that distinguishes Amondys 45 from a one-time gene therapy. Amondys 45 is lifelong, weekly, and dosed by weight. As your son grows, the dose grows, and the annual cost grows.

The Amondys 45 annual drug price in 2026 sits in an indicative range of roughly USD 700,000 to 1,200,000 per year, depending on body weight, or approximately AED 2.6 to 4.4 million per year. For a typical paediatric patient starting therapy at age 6 to 8, cumulative drug cost over a lifetime can reach USD 30 to 50 million plus at current pricing. That is the manufacturer's price for the drug only. The full cost of care includes the pre-treatment workup, vascular access placement if a port is chosen, the weekly infusion-centre fees or home-infusion-programme fees, quarterly renal and motor monitoring, periodic cardiac and pulmonary assessment, and our coordination fee.

When we issue a quote at intake, we separate every line: drug per quarter, qualified-centre or home-infusion fees, vascular access procedure costs if applicable, monitoring labs, our coordination fee. Nothing is bundled. We do not put a markup on the manufacturer's drug price. The coordination fee is disclosed in writing before any funds move.

Insurance coverage of Amondys 45 in the UAE is uneven and tends to be evaluated case by case under prior-authorisation pathways. Daman has reimbursed exon-skipping therapies for certain employer plans through prior authorisation; private insurers vary widely and most do not consider DMD exon-skipping therapy a standard covered benefit. We supply your insurer with the documentation packet at no charge. We do not process the claim or guarantee coverage. Most UAE Amondys 45 cases to date that have moved forward have done so as cash-pay arrangements with partial reimbursement where available.

A direct point: families weighing Amondys 45 against Elevidys for an exon-45-skip-amenable son are weighing a roughly AED 11 to 13 million one-time cost (Elevidys) against an indefinite AED 2.6 to 4.4 million annual cost (Amondys 45). That arithmetic has implications beyond the first year. Your paediatric neurologist will frame the clinical comparison; we will frame the financial-planning comparison honestly.

Life on weekly infusion

The peri-infusion protocol is light compared with gene therapy. Amondys 45 is not a one-time event with months of post-infusion monitoring; it is a routine. Hypersensitivity reactions can occur and the first several infusions are typically observed at the qualified centre, but once stable, many patients move to a routine of weekly infusions of 35 to 60 minutes each.

The practical implication for the family is that the infusion fits into the weekly rhythm of the household. Many UAE families schedule the infusion for a Saturday morning, before the school week, so school attendance is preserved. Home infusion programmes, where the qualified centre arranges a nurse to administer the infusion at home, are an option for stable patients in some emirates and can simplify the logistics further. Vascular access through a port reduces the friction of weekly peripheral cannulation, which is a real consideration for a child who will be on this therapy for decades.

Quarterly visits to the paediatric neurology team cover renal function (serum creatinine, urinalysis), motor function (6-minute walk test, North Star), pulmonary function (FVC), and at scheduled intervals echocardiography. These are not Amondys 45 specific; they are the standard surveillance schedule for DMD management with Amondys 45 layered in.

Religious and ethical considerations

Casimersen is a synthetic antisense oligonucleotide. It contains no animal-source material. Halal and kosher status are not in question. For Muslim families thinking through the religious-ethical dimension, the Islamic bioethics consensus on disease-modifying therapies that preserve life and function is broadly permissive, and families typically consult with their religious advisors before committing to a lifelong therapy. The "lifelong commitment" aspect of Amondys 45 sometimes invites deeper religious consultation than a one-time therapy would; we have found that the families who proceed have usually taken between two and six weeks from first call to engagement.

When Amondys 45 is not the right option

We will name the situations where Amondys 45 is not the right page directly.

If your son's mutation is not amenable to exon 45 skipping, Amondys 45 is the wrong drug. Depending on the deletion boundary, the right drug may be Exondys 51, Vyondys 53, or Viltepso. If your son is ambulatory and 4 or older with a confirmed DMD mutation of any exon position, Elevidys gene therapy may be an option (with the FDA boxed-warning considerations we discuss on the Elevidys page).

If your son has clinically significant renal impairment, the renal toxicity warning on Amondys 45 puts the therapy on hold until the renal picture is workable. This is a conversation between you and your paediatric neurologist, not a categorical rule.

If your son has been diagnosed with a non-DMD muscular dystrophy (Becker, limb-girdle, fascioscapulohumeral, others), Amondys 45 does not apply. The exon-skipping mechanism is specific to DMD-gene splicing.

In all of these situations, reach out anyway. We will walk through what the right pathway looks like for your son's specific picture.

What Reserve Meds does, and what we do not do

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For a UAE family pursuing Amondys 45, our scope is the regulatory documentation packet, the EDE filing in collaboration with your treating hospital's import pharmacy, the sourcing logistics from the manufacturer's authorised US distribution through DSCSA-compliant chain of custody, cold-chain shipment of the weekly supply to the qualified UAE centre or home-infusion programme, the renewal-cycle calendar so supply continuity is never at risk, and named case-lead coordination from intake forward.

Reserve Meds is not your son's prescriber. We do not practise medicine. We do not manufacture Amondys 45. We do not own or operate the infusion centre. We are not your insurer. Clinical decisions stay with your paediatric neurologist and the qualified centre; we are the operational layer that turns those decisions into a coordinated case.

We work cash-pay. Our coordination fee is disclosed in writing. We will not start work without a signed engagement.

What to do if you want to start

The first concrete step is a call with our case-lead so we can confirm whether Amondys 45 is the right consideration for your son. If genetic confirmation of an exon-45-skip-amenable mutation is already in hand, we move directly into documentation work. If not, we route through to the right paediatric genetics service first.

Most families reach us first on WhatsApp, which is the medium we hold open during UAE business hours and on weekends for active cases.

Start your son's case on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating paediatric neurologist.

Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.